N. Latov, Diagnosis and treatment of chronic acquired demyelinating polyneuropathies, Nature Reviews Neurology, vol.60, issue.8, pp.435-446, 2014.
DOI : 10.1517/13543784.2012.685650

J. Katz, D. Saperstein, G. Gronseth, A. Amato, and R. Barohn, Distal acquired demyelinating symmetric neuropathy, Neurology, vol.54, issue.3, pp.615-620, 2000.
DOI : 10.1212/WNL.54.3.615

N. Latov, W. Sherman, and R. Nemni, Plasma-Cell Dyscrasia and Peripheral Neuropathy with a Monoclonal Antibody to Peripheral-Nerve Myelin, New England Journal of Medicine, vol.303, issue.11, pp.618-621, 1980.
DOI : 10.1056/NEJM198009113031105

I. Smith, S. Kahn, and B. Lacey, CHRONIC DEMYELINATING NEUROPATHY ASSOCIATED WITH BENIGN IGM PARAPROTEINAEMIA, Brain, vol.106, issue.1, pp.169-195, 1983.
DOI : 10.1093/brain/106.1.169

R. Kyle, T. Therneau, and S. Rajkumar, Prevalence of Monoclonal Gammopathy of Undetermined Significance, New England Journal of Medicine, vol.354, issue.13, pp.1362-1369, 2006.
DOI : 10.1056/NEJMoa054494

M. Gertz, Waldenström macroglobulinemia: 2013 update on diagnosis, risk stratification, and management, Am J Hematol. 2013, vol.88, issue.8, pp.703-711

M. Sant, C. Allemani, and C. Tereanu, Incidence of hematologic malignancies in Europe by morphologic subtype: results of the HAEMACARE project, Blood, vol.116, issue.19, pp.3724-3734, 2010.
DOI : 10.1182/blood-2010-05-282632

N. Van-de-donk, A. Palumbo, and H. Johnsen, The clinical relevance and management of monoclonal gammopathy of undetermined significance and related disorders: recommendations from the European Myeloma Network, Haematologica, vol.99, issue.6, pp.984-996, 2014.
DOI : 10.3324/haematol.2013.100552

R. Kyle, B. Durie, and S. Rajkumar, Monoclonal gammopathy of undetermined significance (MGUS) and smoldering (asymptomatic) multiple myeloma: IMWG consensus perspectives risk factors for progression and guidelines for monitoring and management, Leukemia, vol.102, issue.6, pp.1121-1127, 2010.
DOI : 10.1182/blood-2007-08-108357

T. Levine, A. Pestronk, and J. Florence, Peripheral neuropathies in Waldenstrom's macroglobulinaemia, Journal of Neurology, Neurosurgery & Psychiatry, vol.77, issue.2, pp.224-228, 2006.
DOI : 10.1136/jnnp.2005.071175

S. Ramchandren and R. Lewis, Monoclonal gammopathy and neuropathy, Current Opinion in Neurology, vol.22, issue.5, 2009.
DOI : 10.1097/WCO.0b013e32832fd563

A. Steck, A. Stalder, and S. Renaud, Anti-myelin-associated glycoprotein neuropathy, Current Opinion in Neurology, vol.19, issue.5, pp.458-463, 2006.
DOI : 10.1097/01.wco.0000245368.36576.0d

R. Hadden, European Federation of Neurological Societies/Peripheral Nerve Society guideline on management of paraproteinaemic demyelinating neuropathies: report of a joint task force of the European Federation of Neurological Societies and the Peripheral Nerve Society*, European Journal of Neurology, vol.158, issue.10, pp.809-818, 2006.
DOI : 10.1182/blood-2004-05-2046

E. Nobile-orazio, S. Barbieri, and L. Baldini, Peripheral neuropathy in monoclonal gammopathy of undetermined significance: prevalence and immunopathogenetic studies, Acta Neurologica Scandinavica, vol.24, issue.6, pp.383-390, 1992.
DOI : 10.1111/j.1600-0404.1992.tb06033.x

M. Vrethem, M. Cruz, H. Wen-xin, C. Malm, H. Holmgren et al., Clinical, neurophysiological and immunological evidence of polyneuropathy in patients with monoclonal gammopathies, Journal of the Neurological Sciences, vol.114, issue.2, pp.193-199, 1993.
DOI : 10.1016/0022-510X(93)90297-C

J. Kelly, Peripheral neuropathies associated with monoclonal gammopathies of undetermined significance, Rev Neurol Dis, vol.5, issue.1, pp.14-22, 2008.

M. Eurelings, H. Lokhorst, S. Kalmijn, J. Wokke, and N. Notermans, Malignant transformation in polyneuropathy associated with monoclonal gammopathy, Neurology, vol.64, issue.12, pp.2079-2084, 2005.
DOI : 10.1212/01.WNL.0000176296.79088.9A

N. Alkhawajah, S. Dunnigan, and V. Bril, Comparison of monoclonal gammopathy of undetermined significance-associated neuropathy and chronic inflammatory demyelinating polyneuropathy patients, Journal of Neurology, vol.77, issue.8, pp.1485-1491, 2014.
DOI : 10.1007/s00415-014-7357-0

E. Nobile-orazio, E. Manfredini, and M. Carpo, Frequency and clinical correlates of anti-neural IgM antibodies in neuropathy associated with IgM monoclonal gammopathy, Annals of Neurology, vol.38, issue.3, pp.416-424, 1994.
DOI : 10.1002/ana.410360313

S. Kuwabara, A. Dispenzieri, K. Arimura, and S. Misawa, Treatment for POEMS (polyneuropathy, organomegaly, endocrinopathy, M-protein, and skin changes) syndrome, Cochrane Database Syst Rev, issue.4, p.6828, 2008.

N. Latov and S. Renaud, Effector mechanisms in anti-MAG antibody-mediated and other demyelinating neuropathies, Journal of the Neurological Sciences, vol.220, issue.1-2, pp.127-129, 2004.
DOI : 10.1016/j.jns.2004.03.012

S. Monaco, B. Bonetti, and S. Ferrari, Complement-Mediated Demyelination in Patients with IgM Monoclonal Gammopathy and Polyneuropathy, New England Journal of Medicine, vol.322, issue.10, pp.649-652, 1990.
DOI : 10.1056/NEJM199003083221002

P. Braun, D. Frail, and N. Latov, Myelin-Associated Glycoprotein Is the Antigen for a Monoclonal IgM in Polyneuropathy, Journal of Neurochemistry, vol.12, issue.5, pp.1261-1265, 1982.
DOI : 10.1073/pnas.76.9.4350

R. Quarles, Myelin-associated glycoprotein (MAG): past, present and beyond, Journal of Neurochemistry, vol.18, issue.0, pp.1431-1448, 2007.
DOI : 10.1111/j.1471-4159.1991.tb08260.x

R. Schnaar and P. Lopez, Myelin-associated glycoprotein and its axonal receptors, Journal of Neuroscience Research, vol.102, issue.15, pp.3267-3276, 2009.
DOI : 10.1002/jnr.21992

URL : http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2892843

M. Keita, L. Magy, A. Heape, L. Richard, M. Piaser et al., Immunocytological Studies of L-MAG Expression Regulation during Myelination of Embryonic Brain Cell Cocultures, Developmental Neuroscience, vol.24, issue.6, pp.495-503, 2002.
DOI : 10.1159/000069360

M. Schachner and U. Bartsch, Multiple functions of the myelin-associated glycoprotein MAG (siglec-4a) in formation and maintenance of myelin, Glia, vol.18, issue.2, pp.154-165, 2000.
DOI : 10.1002/(SICI)1098-1136(20000115)29:2<154::AID-GLIA9>3.0.CO;2-3

J. Huang, Y. Wang, and W. Gu, Expression and function of myelin-associated proteins and their common receptor NgR on oligodendrocyte progenitor cells, Brain Research, vol.1437, pp.1-15
DOI : 10.1016/j.brainres.2011.12.008

V. Pernet, S. Joly, F. Christ, L. Dimou, and M. Schwab, Nogo-A and Myelin-Associated Glycoprotein Differently Regulate Oligodendrocyte Maturation and Myelin Formation, Journal of Neuroscience, vol.28, issue.29, pp.7435-7444, 2008.
DOI : 10.1523/JNEUROSCI.0727-08.2008

R. Quarles, A Hypothesis About the Relationship of Myelin-Associated Glycoprotein???s Function in Myelinated Axons to its Capacity to Inhibit Neurite Outgrowth, Neurochemical Research, vol.206, issue.1, 2009.
DOI : 10.1007/s11064-008-9668-y

N. Fujita, A. Kemper, and J. Dupree, The cytoplasmic domain of the large myelin-associated glycoprotein isoform is needed for proper CNS but not peripheral nervous system myelination

G. Blume, A. Pestronk, and L. Goodnough, Anti-MAG antibody-associated polyneuropathies: Improvement following immunotherapy with monthly plasma exchange and IV cyclophosphamide, Neurology, vol.45, issue.8, pp.1577-1580, 1995.
DOI : 10.1212/WNL.45.8.1577

E. Oksenhendler, S. Chevret, J. Léger, J. Louboutin, A. Bussel et al., Plasma exchange and chlorambucil in polyneuropathy associated with monoclonal IgM gammopathy. IgM-associated Polyneuropathy Study Group., Journal of Neurology, Neurosurgery & Psychiatry, vol.59, issue.3, pp.243-247, 1995.
DOI : 10.1136/jnnp.59.3.243

A. Ilyas, Y. Gu, M. Dalakas, R. Quarles, and S. Bhatt, Induction of experimental ataxic sensory neuronopathy in cats by immunization with purified SGPG, Journal of Neuroimmunology, vol.193, issue.1-2, pp.87-93, 2008.
DOI : 10.1016/j.jneuroim.2007.10.025

B. Chassande, J. Léger, and A. Younes-chennoufi, Peripheral neuropathy associated with IgM monoclonal gammopathy: Correlations between M-protein antibody activity and clinical/electrophysiological features in 40 cases, Muscle & Nerve, vol.56, issue.1, pp.55-62, 1998.
DOI : 10.1002/(SICI)1097-4598(199801)21:1<55::AID-MUS8>3.0.CO;2-F

E. Ellie, A. Vital, A. Steck, J. Boiron, C. Vital et al., Neuropathy associated with ?benign? anti-myelin-associated glycoprotein IgM gammopathy: Clinical, immunological, neurophysiological pathological findings and response to treatment in 33 cases, Journal of Neurology, vol.238, issue.Suppl 44, 1996.
DOI : 10.1007/BF00878529

M. Capasso, F. Torrieri, D. Muzio, A. , D. Angelis et al., CAN ELECTROPHYSIOLOGY DIFFERENTIATE POLYNEUROPATHY WITH ANTI-MAG/SGPG ANTIBODIES FROM CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY?, Journal of the Peripheral Nervous System, vol.7, issue.4, pp.346-353, 2002.
DOI : 10.1046/j.1529-8027.2002.02032_1.x

T. Maisonobe, B. Chassande, M. Vérin, M. Jouni, J. Léger et al., Chronic dysimmune demyelinating polyneuropathy: a clinical and electrophysiological study of 93 patients., Journal of Neurology, Neurosurgery & Psychiatry, vol.61, issue.1, pp.36-42, 1996.
DOI : 10.1136/jnnp.61.1.36

P. Bain, T. Britton, and I. Jenkins, Tremor associated with benign IgM paraproteinaemic neuropathy, Brain, vol.119, issue.3, pp.789-799, 1996.
DOI : 10.1093/brain/119.3.789

S. Pedersen, S. Pullman, N. Latov, and T. Brannagan, Physiological tremor analysis of patients with anti-myelin-associated glycoprotein associated neuropathy and tremor. Muscle Nerve, pp.38-44, 1997.

C. Klein, J. Moon, and M. Mauermann, The neuropathies of Waldenström's macroglobulinemia (WM) and IgM-MGUS, Can J Neurol Sci J Can Sci Neurol, 2011.

E. Vanhoutte, C. Faber, and I. Merkies, 196th ENMC international workshop: Outcome measures in inflammatory peripheral neuropathies 8???10 February 2013, Naarden, The Netherlands, Neuromuscular Disorders, vol.23, issue.11, pp.924-933, 2013.
DOI : 10.1016/j.nmd.2013.06.006

R. Hughes, S. Bensa, and H. Willison, Randomized controlled trial of intravenous immunoglobulin versus oral prednisolone in chronic inflammatory demyelinating polyradiculoneuropathy, Annals of Neurology, vol.40, issue.2, pp.195-201, 2001.
DOI : 10.1002/ana.1088

I. Merkies and P. Schmitz, Getting closer to patients: the INCAT Overall Disability Sum Score relates better to patients' own clinical judgement in immune-mediated polyneuropathies, Journal of Neurology, Neurosurgery & Psychiatry, vol.77, issue.8, pp.970-972, 2006.
DOI : 10.1136/jnnp.2005.076174

I. Merkies, P. Schmitz, F. Van-der-meché, J. Samijn, and P. Van-doorn, Inflammatory Neuropathy Cause and Treatment (INCAT) group. Clinimetric evaluation of a new overall disability scale in immune mediated polyneuropathies, J Neurol Neurosurg Psychiatry, 2002.

R. Graham and R. Hughes, A modified peripheral neuropathy scale: the Overall Neuropathy Limitations Scale, Journal of Neurology, Neurosurgery & Psychiatry, vol.77, issue.8, pp.973-976, 2006.
DOI : 10.1136/jnnp.2005.081547

S. Van-nes, E. Vanhoutte, and P. Van-doorn, Rasch-built Overall Disability Scale (R-ODS) for immune-mediated peripheral neuropathies, Neurology, vol.76, issue.4, pp.337-345, 2011.
DOI : 10.1212/WNL.0b013e318208824b

I. Merkies, P. Schmitz, F. Van-der-meché, and P. Van-doorn, Psychometric evaluation of a new sensory scale in immune-mediated polyneuropathies. Inflammatory Neuropathy Cause and Treatment (INCAT) Group, Neurology. Feb, vol.2254, issue.4, pp.943-949, 2000.

R. Kleyweg, F. Van-der-meché, and P. Schmitz, Interobserver agreement in the assessment of muscle strength and functional abilities in Guillain-Barré syndrome. Muscle Nerve, 1991.

I. Merkies, P. Schmitz, F. Van-der-meché, J. Samijn, and P. Van-doorn, Quality of life complements traditional outcome measures in immune-mediated polyneuropathies, Neurology, vol.59, issue.1, pp.84-91, 2002.
DOI : 10.1212/WNL.59.1.84

T. Quinn, J. Dawson, M. Walters, and K. Lees, Reliability of the Modified Rankin Scale: A Systematic Review, Stroke, vol.40, issue.10, pp.3393-3395, 2009.
DOI : 10.1161/STROKEAHA.109.557256

H. Franssen and N. Notermans, Length dependence in polyneuropathy associated with IgM gammopathy, Annals of Neurology, vol.58, issue.2, pp.365-371, 2006.
DOI : 10.1002/ana.20785

A. Radziwill, A. Steck, S. Renaud, and P. Fuhr, Distal motor latency and residual latency as sensitive markers of anti-MAG polyneuropathy, Journal of Neurology, vol.250, issue.8, pp.962-966, 2003.
DOI : 10.1007/s00415-003-1128-7

D. Kaku, J. England, and A. Sumner, Distal accentuation of conduction slowing in polyneuropathy associated with antibodies to myelin-associated glycoprotein and sulphated glucuronyl paragloboside, Brain, vol.117, issue.5, pp.941-947, 1994.
DOI : 10.1093/brain/117.5.941

S. Attarian, J. Azulay, J. Boucraut, N. Escande, and J. Pouget, Terminal latency index and modified F ratio in distinction of chronic demyelinating neuropathies, Clinical Neurophysiology, vol.112, issue.3, pp.457-463, 2001.
DOI : 10.1016/S1388-2457(01)00469-2

D. Cocito, G. Isoardo, and P. Ciaramitaro, Terminal latency index in polyneuropathy with IgM paraproteinemia and anti-MAG antibody. Muscle Nerve, pp.1278-1282, 2001.

V. Lupu, C. Mora, J. Dambrosia, J. Meer, M. Dalakas et al., Terminal latency index in neuropathy with antibodies against myelin-associated glycoproteins. Muscle Nerve, 2007.

W. Trojaborg, G. Galassi, A. Hays, R. Lovelace, M. Alkaitis et al., Electrophysiologic study of experimental demyelination induced by serum of patients with IgM M proteins and neuropathy, Neurology, vol.39, issue.12, pp.1581-1586, 1989.
DOI : 10.1212/WNL.39.12.1581

A. Stork, W. Van-der-pol, H. Franssen, B. Jacobs, and N. Notermans, Clinical phenotype of patients with neuropathy associated with monoclonal gammopathy: a comparative study and a review of the literature, Journal of Neurology, vol.260, issue.7, pp.1398-1404
DOI : 10.1007/s00415-014-7354-3

M. Kuijf, M. Eurelings, and A. Tio-gillen, Detection of anti-MAG antibodies in polyneuropathy associated with IgM monoclonal gammopathy, Neurology, vol.73, issue.9, pp.688-695, 2009.
DOI : 10.1212/WNL.0b013e3181b59a80

C. Caudie, F. Kaygisiz, and P. Jaquet, Diagnostic value of autoantibodies to MAG by ELISA Bühlmann in 117 immune-mediated peripheral neuropathies associated with monoclonal IgM to SGPG, Ann Biol Clin, vol.64, issue.4, pp.353-359, 2006.

L. Van-den-berg, A. Hays, and E. Nobile-orazio, Anti-MAG and anti-SGPG antibodies in neuropathy. Muscle Nerve, pp.637-643, 1996.

M. Weiss, M. Dalakas, C. Lauter, H. Willison, and R. Quarles, Variability in the binding of anti-MAG and anti-SGPG antibodies to target antigens in demyelinating neuropathy and IgM paraproteinemia, Journal of Neuroimmunology, vol.95, issue.1-2, pp.174-184, 1999.
DOI : 10.1016/S0165-5728(98)00247-1

M. Dalakas, T. Pathogenesis, and . Neuropathy, Pathogenesis and Treatment of Anti-MAG Neuropathy, Current Treatment Options in Neurology, vol.29, issue.1, pp.71-83, 2010.
DOI : 10.1007/s11940-010-0065-x

M. Lunn, T. Crawford, R. Hughes, J. Griffin, and K. Sheikh, Anti-myelin-associated glycoprotein antibodies alter neurofilament spacing, Brain, vol.125, issue.4, pp.904-911, 2002.
DOI : 10.1093/brain/awf072

URL : http://doi.org/10.1093/brain/awf072

J. Vallat, F. Tabaraud, P. Sindou, P. Preux, A. Vandenberghe et al., Myelin widenings and MGUS-IgA: An immunoelectron microscopic study, Annals of Neurology, vol.117, issue.6, pp.808-811, 2000.
DOI : 10.1002/1531-8249(200006)47:6<808::AID-ANA15>3.0.CO;2-8

J. Mendell, Z. Sahenk, and J. Whitaker, Polyneuropathy and IgM monoclonal gammopathy: Studies on the pathogenetic role of anti-myelin-associated glycoprotein antibody, Annals of Neurology, vol.34, issue.3, pp.243-254, 1985.
DOI : 10.1002/ana.410170305

E. Nobile-orazio, N. Meucci, L. Baldini, D. Troia, A. Scarlato et al., Long-term prognosis of neuropathy associated with anti-MAG IgM M-proteins and its relationship to immune therapies, Brain, vol.123, issue.4, pp.710-717, 2000.
DOI : 10.1093/brain/123.4.710

N. Notermans, J. Wokke, H. Lokhorst, H. Franssen, Y. Van-der-graaf et al., Polyneuropathy associated with monoclonal gammopathy of undetermined significance, Brain, vol.117, issue.6, pp.1385-1393, 1994.
DOI : 10.1093/brain/117.6.1385

I. Smith, The natural history of chronic demyelinating neuropathy associated with benign IgM paraproteinaemia, Brain, vol.117, issue.5, pp.949-957, 1994.
DOI : 10.1093/brain/117.5.949

S. Ponsford, H. Willison, J. Veitch, R. Morris, and P. Thomas, Long-term clinical and neurophysiological follow-up of patients with peripheral, neuropathy associated with benign monoclonal gammopathy, Muscle & Nerve, vol.238, issue.2, pp.164-174, 2000.
DOI : 10.1002/(SICI)1097-4598(200002)23:2<164::AID-MUS4>3.0.CO;2-Y

R. Kyle, T. Therneau, and A. Dispenzieri, Immunoglobulin M Monoclonal Gammopathy of Undetermined Significance and Smoldering Waldenstr??m Macroglobulinemia, Clinical Lymphoma Myeloma and Leukemia, vol.13, issue.2, pp.184-186
DOI : 10.1016/j.clml.2013.02.005

S. Kristinsson, M. Björkholm, and O. Landgren, Survival in Monoclonal Gammopathy of Undetermined Significance and Waldenstr??m Macroglobulinemia, Clinical Lymphoma Myeloma and Leukemia, vol.13, issue.2, pp.187-190
DOI : 10.1016/j.clml.2013.02.010

J. Berenson, K. Anderson, and R. Audell, Monoclonal gammopathy of undetermined significance: a consensus statement, British Journal of Haematology, vol.22, issue.Suppl. 2, pp.28-38, 2010.
DOI : 10.1111/j.1365-2141.2010.08207.x

O. Decaux, E. Laurat, A. Perlat, C. Cazalets, P. Jego et al., Systemic manifestations of monoclonal gammopathy, European Journal of Internal Medicine, vol.20, issue.5, pp.457-461, 2009.
DOI : 10.1016/j.ejim.2009.01.001

S. Ansell, R. Kyle, and C. Reeder, Diagnosis and Management of Waldenstr??m Macroglobulinemia: Mayo Stratification of Macroglobulinemia and Risk-Adapted Therapy (mSMART) Guidelines, Mayo Clinic Proceedings, vol.85, issue.9, pp.824-833, 2010.
DOI : 10.4065/mcp.2010.0304

M. Lunn and E. Nobile-orazio, Immunotherapy for IgM anti-myelin-associated glycoprotein paraprotein-associated peripheral neuropathies, Cochrane Database Syst Rev, vol.5, p.2827, 2012.

P. Dyck, P. Low, and A. Windebank, Plasma Exchange in Polyneuropathy Associated with Monoclonal Gammopathy of Undetermined Significance, New England Journal of Medicine, vol.325, issue.21, pp.1482-1486, 1991.
DOI : 10.1056/NEJM199111213252105

K. Gorson, A. Ropper, D. Weinberg, and R. Weinstein, Treatment experience in patients with anti-myelin-associated glycoprotein neuropathy. Muscle Nerve, pp.778-786, 2001.

N. Notermans, M. Vermeulen, and H. Lokhorst, Pulsed high-dose dexamethasone treatment of polyneuropathy associated with monoclonal gammopathy, Journal of Neurology, vol.244, issue.7, pp.462-463, 1997.
DOI : 10.1007/s004150050124

G. Comi, L. Roveri, and A. Swan, A randomised controlled trial of intravenous immunoglobulin in IgM paraprotein associated demyelinating neuropathy, Journal of Neurology, vol.249, issue.10, pp.1370-1377, 2002.
DOI : 10.1007/s00415-002-0808-z

M. Dalakas, R. Quarles, and R. Farrer, A controlled study of intravenous immunoglobulin in demyelinating neuropathy with IgM gammopathy, Annals of Neurology, vol.322, issue.5, pp.792-795, 1996.
DOI : 10.1002/ana.410400516

X. Mariette, J. Brouet, and S. Chevret, A randomised double blind trial versus placebo does not confirm the benefit of alpha -interferon in polyneuropathy associated with monoclonal IgM, Journal of Neurology, Neurosurgery & Psychiatry, vol.69, issue.2
DOI : 10.1136/jnnp.69.2.279

X. Mariette, C. Chastang, P. Clavelou, J. Louboutin, J. Leger et al., A randomised clinical trial comparing interferon-alpha and intravenous immunoglobulin in polyneuropathy associated with monoclonal IgM, Journal of Neurology, Neurosurgery & Psychiatry, vol.63, issue.1, pp.28-34, 1997.
DOI : 10.1136/jnnp.63.1.28

M. Lunn and E. Nobile-orazio, Immunotherapy for IgM anti-myelin-associated glycoprotein paraprotein-associated peripheral neuropathies, Cochrane Database Syst Rev Online, issue.2, p.2827, 2006.

J. Niermeijer, M. Eurelings, and M. Van-der-linden, Intermittent cyclophosphamide with prednisone versus placebo for polyneuropathy with IgM monoclonal gammopathy, Neurology, vol.69, issue.1, pp.50-59, 2007.
DOI : 10.1212/01.wnl.0000265055.28218.cc

N. Notermans, H. Lokhorst, and H. Franssen, Intermittent cyclophosphamide and prednisone treatment of polyneuropathy associated with monoclonal gammopathy of undetermined significance, Neurology, vol.47, issue.5, pp.1227-1233, 1996.
DOI : 10.1212/WNL.47.5.1227

J. Niermeijer, M. Eurelings, and H. Lokhorst, Neurologic and hematologic response to fludarabine treatment in IgM MGUS polyneuropathy, Neurology, vol.67, issue.11, pp.2076-2079, 2006.
DOI : 10.1212/01.wnl.0000247671.58066.21

H. Wilson, M. Lunn, S. Schey, and R. Hughes, Successful treatment of IgM paraproteinaemic neuropathy with fludarabine, Journal of Neurology, Neurosurgery & Psychiatry, vol.66, issue.5, pp.575-580, 1999.
DOI : 10.1136/jnnp.66.5.575

A. Ghosh, T. Littlewood, and M. Donaghy, Cladribine in the treatment of IgM paraproteinemic polyneuropathy, Neurology, vol.59, issue.8, pp.1290-1291, 2002.
DOI : 10.1212/WNL.59.8.1290

S. Rudnicki, S. Harik, M. Dhodapkar, B. Barlogie, and D. Eidelberg, Nervous system dysfunction in Waldenstrom's macroglobulinemia: Response to treatment, Neurology, vol.51, issue.4, pp.1210-1213, 1998.
DOI : 10.1212/WNL.51.4.1210

L. Benedetti, C. Briani, and M. Grandis, Predictors of response to rituximab in patients with neuropathy and anti?myelin associated glycoprotein immunoglobulin M, Journal of the Peripheral Nervous System, vol.322, issue.2, pp.102-107, 2007.
DOI : 10.1212/01.wnl.0000201193.00382.b3

E. Kimby, Tolerability and safety of rituximab (MabThera??), Cancer Treatment Reviews, vol.31, issue.6, 2005.
DOI : 10.1016/j.ctrv.2005.05.007

C. Tan and I. Koralnik, Progressive multifocal leukoencephalopathy and other disorders caused by JC virus: clinical features and pathogenesis, The Lancet Neurology, vol.9, issue.4, pp.425-437
DOI : 10.1016/S1474-4422(10)70040-5

URL : http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2880524

E. Delmont, P. Jeandel, C. Benaïm, E. Rosenthal, J. Fuzibet et al., Treatment with rituximab in patients with polyneuropathy with anti-MAG antibodies, Journal of Neurology, vol.80, issue.9, 2011.
DOI : 10.1007/s00415-011-5994-0

URL : https://hal.archives-ouvertes.fr/hal-00703179

J. Niermeijer, M. Eurelings, and H. Lokhorst, Rituximab for polyneuropathy with IgM monoclonal gammopathy, Journal of Neurology, Neurosurgery & Psychiatry, vol.80, issue.9, pp.1036-1039, 2009.
DOI : 10.1136/jnnp.2008.155325

S. Renaud, M. Gregor, and P. Fuhr, Rituximab in the treatment of polyneuropathy associated with anti-MAG antibodies. Muscle Nerve, pp.611-615, 2003.

S. Renaud, P. Fuhr, and M. Gregor, High-dose rituximab and anti-MAG-associated polyneuropathy, Neurology, vol.66, issue.5, pp.742-744, 2006.
DOI : 10.1212/01.wnl.0000201193.00382.b3

M. Dalakas, G. Rakocevic, and M. Salajegheh, Placebo-controlled trial of rituximab in IgM anti-myelin-associated glycoprotein antibody demyelinating neuropathy, Annals of Neurology, vol.358, issue.5 pt 1, 2009.
DOI : 10.1002/ana.21577

J. Léger, K. Viala, and G. Nicolas, Placebo-controlled trial of rituximab in IgM anti-myelin-associated glycoprotein neuropathy, Neurology, vol.80, issue.24, pp.2217-2225, 2013.
DOI : 10.1212/WNL.0b013e318296e92b

M. Kodaira and K. Yamamoto, Rituximab Improves Subclinical Temporal Dispersion of Distal Compound Muscle Action Potential in Anti-MAG/SGPG Neuropathy Associated with Waldenstr??m Macroglobulinemia: A Case Report, Case Reports in Neurology, vol.5, issue.1, pp.34-39
DOI : 10.1159/000348395

M. Gironi, M. Saresella, and L. Ceresa, Clinical and immunological worsening in a patient affected with Waldenstrom macroglobulinemia and anti-mag neuropathy after treatment with rituximab, Haematologica, vol.91, issue.6, p.17, 2006.

E. Sala, F. Robert-varvat, S. Paul, J. Camdessanché, and J. Antoine, Acute neurological worsening after Rituximab treatment in patients with anti-MAG neuropathy, Journal of the Neurological Sciences, vol.345, issue.1-2, 2014.
DOI : 10.1016/j.jns.2014.07.055

A. Stork, N. Notermans, A. Vrancken, D. Cornblath, and W. Van-der-pol, Rapid worsening of IgM anti-MAG demyelinating polyneuropathy during rituximab treatment, Journal of the Peripheral Nervous System, vol.61, issue.Suppl. 3, pp.189-191
DOI : 10.1111/jns5.12018

I. Ghobrial, R. Fonseca, and P. Greipp, Initial immunoglobulin M ?flare? after rituximab therapy in patients diagnosed with Waldenstrom macroglobulinemia, Cancer, vol.1, issue.11, pp.2593-2598, 2004.
DOI : 10.1002/cncr.20658

M. Hospital, K. Viala, and S. Dragomir, Immunotherapy-based regimen in anti-MAG neuropathy: results in 45 patients, Haematologica, vol.98, issue.12, pp.155-157, 2013.
DOI : 10.3324/haematol.2013.087213

B. Gruson, K. Ghomari, and M. Beaumont, Long-term response to rituximab and fludarabine combination in IgM anti-myelin-associated glycoprotein neuropathy, Journal of the Peripheral Nervous System, vol.66, issue.3, pp.180-185, 2011.
DOI : 10.1111/j.1529-8027.2011.00343.x

A. Pestronk, J. Florence, T. Miller, R. Choksi, M. Lozi et al., Treatment of IgM antibody associated polyneuropathies using rituximab, Journal of Neurology, Neurosurgery & Psychiatry, vol.74, issue.4, 2003.
DOI : 10.1136/jnnp.74.4.485

K. Anderson, M. Alsina, and W. Bensinger, Waldenström's macroglobulinemia/lymphoplasmacytic lymphoma, version 2.2013. J Natl Compr Cancer Netw JNCCN, pp.1211-1219, 2012.
DOI : 10.6004/jnccn.2012.0128

J. Antoine, A. Steck, and D. Michel, Fatal peripheral neuropathy with predominant motor involvement associated with anti-MAG IgM monoclonal gammapathy], Rev Neurol, vol.149, pp.8-9496, 1993.

Y. Kawagashira, N. Kondo, and N. Atsuta, IgM MGUS anti-MAG neuropathy with predominant muscle weakness and extensive muscle atrophy. Muscle Nerve, 2010.

M. Luigetti, F. Madia, A. Conte, P. Tonali, and M. Sabatelli, Neuropathy with Predominant Small Fiber Involvement Associated with Abnormal Anti-MAG Titer, Internal Medicine, vol.49, issue.23, pp.2627-2629, 2010.
DOI : 10.2169/internalmedicine.49.4200

C. Bridel, J. Horvath, M. Kurian, A. Truffert, A. Steck et al., Multifocal motor neuropathy with high titers of anti-MAG antibodies, Journal of the Peripheral Nervous System, vol.68, issue.2, pp.10-1111, 2014.
DOI : 10.1111/jns5.12069

F. Valldeoriola, F. Graus, and A. Steck, Delayed apperance of anti-myelin-associated glycoprotein antibodies in a patient with chronic demyelinating polyneuropathy, Annals of Neurology, vol.26, issue.3, pp.394-396, 1993.
DOI : 10.1002/ana.410340314

R. Gregory, P. Thomas, and R. King, Coexistence of hereditary motor and sensory neuropathy type IA and IGM paraproteinemic neuropathy, Annals of Neurology, vol.339, issue.6, pp.649-652, 1993.
DOI : 10.1002/ana.410330615

T. Jensen, H. Schrøder, and V. Jønsson, IgM monoclonal gammopathy and neuropathy in two siblings., Journal of Neurology, Neurosurgery & Psychiatry, vol.51, issue.10, pp.1308-1315, 1988.
DOI : 10.1136/jnnp.51.10.1308

S. Manschot, N. Notermans, L. Van-den-berg, J. Verschuuren, and H. Lokhorst, Three Families With Polyneuropathy Associated With Monoclonal Gammopathy, Archives of Neurology, vol.57, issue.5, 2000.
DOI : 10.1001/archneur.57.5.740

G. Piscosquito, E. Salsano, C. Ciano, L. Palamara, M. Morbin et al., Coexistence of Charcot-Marie-Tooth disease type 1A and anti-MAG neuropathy, Journal of the Peripheral Nervous System, vol.8, issue.Suppl 3, pp.185-188
DOI : 10.1111/jns5.12029

S. Jurici, A. Laquerrière, and A. Bedat-millet, An Autopsy Case of Amyotrophic Lateral Sclerosis with Waldenstr??m Macroglobulinemia and Anti-MAG Gammopathy, Case Reports in Neurology, vol.3, issue.3, pp.294-300, 2011.
DOI : 10.1159/000335004

M. Luigetti, L. Padua, S. Mazza, P. Rossini, M. Sabatelli et al., Clinical???neurophysiological correlations in a series of patients with IgM-related neuropathy, Clinical Neurophysiology, vol.124, issue.9, pp.1899-1903, 2013.
DOI : 10.1016/j.clinph.2013.02.116

M. Eurelings, N. Notermans, and H. Franssen, MRI of the brachial plexus in polyneuropathy associated with monoclonal gammopathy. Muscle Nerve, pp.1312-1318, 2001.

R. Lombardi, B. Erne, and G. Lauria, IgM deposits on skin nerves in anti-myelin-associated glycoprotein neuropathy, Annals of Neurology, vol.164, issue.2, pp.180-187, 2005.
DOI : 10.1002/ana.20364

A. Stalder, B. Erne, and R. Reimann, Immunoglobulin M Deposition in Cutaneous Nerves of Anti-Myelin-Associated Glycoprotein Polyneuropathy Patients Correlates With Axonal Degeneration, Journal of Neuropathology and Experimental Neurology, vol.68, issue.2, pp.148-158, 2009.
DOI : 10.1097/NEN.0b013e3181958187

M. Lucchetta, L. Padua, and G. Granata, Nerve ultrasound findings in neuropathy associated with anti-myelin-associated glycoprotein antibodies, European Journal of Neurology, vol.260, issue.1, 2014.
DOI : 10.1111/ene.12554

M. Eurelings, K. Moons, and N. Notermans, Neuropathy and IgM M-proteins: Prognostic value of antibodies to MAG, SGPG, and sulfatide, Neurology, vol.56, issue.2, pp.228-233, 2001.
DOI : 10.1212/WNL.56.2.228

J. Niermeijer, K. Fischer, M. Eurelings, H. Franssen, J. Wokke et al., Prognosis of polyneuropathy due to IgM monoclonal gammopathy: A prospective cohort study, Neurology, vol.74, issue.5, pp.406-412, 2010.
DOI : 10.1212/WNL.0b013e3181ccc6b9

D. Cornblath, V. Chaudhry, and K. Carter, Total neuropathy score: Validation and reliability study, Neurology, vol.53, issue.8, pp.1660-1664, 1999.
DOI : 10.1212/WNL.53.8.1660

I. Merkies, P. Schmitz, F. Van-der-meché, J. Samijn, and P. Van-doorn, Psychometric evaluation of a new handicap scale in immune-mediated polyneuropathies. Muscle Nerve, 2002.

L. Broglio and G. Lauria, Worsening after rituximab treatment in anti-mag neuropathy. Muscle Nerve, pp.378-379, 2005.

R. Rojas-garcía, E. Gallardo, and I. De-andrés, Chronic neuropathy with IgM anti-ganglioside antibodies: Lack of long term response to rituximab, Neurology, vol.61, issue.12, pp.1814-1816, 2003.
DOI : 10.1212/01.WNL.0000098996.02934.86

L. Benedetti, E. Zardini, and C. Briani, B-cell-activating factor in rituximab-treated patients with anti-MAG polyneuropathy, Journal of Neurology, Neurosurgery & Psychiatry, vol.82, issue.11, pp.1291-1294, 2011.
DOI : 10.1136/jnnp.2010.222216

T. Davis, A. Grillo-lópez, and C. White, Rituximab Anti-CD20 Monoclonal Antibody Therapy in Non-Hodgkin???s Lymphoma: Safety and Efficacy of Re-Treatment, Journal of Clinical Oncology, vol.18, issue.17, pp.3135-3143, 2000.
DOI : 10.1200/JCO.2000.18.17.3135

E. Keystone, R. Fleischmann, and P. Emery, Safety and efficacy of additional courses of rituximab in patients with active rheumatoid arthritis: An open-label extension analysis, Arthritis & Rheumatism, vol.52, issue.2, pp.3896-3908, 2007.
DOI : 10.1002/art.23059

C. Bayreuther, E. Delmont, M. Borg, and D. Fontaine, Deep brain stimulation of the ventral intermediate thalamic nucleus for severe tremor in anti-MAG neuropathy, Movement Disorders, vol.80, issue.14, pp.2157-2158, 2009.
DOI : 10.1002/mds.22604

J. Mcmaster, G. Gibson, F. Castro-prado, A. Vitali, and C. Honey, NEUROSURGICAL TREATMENT OF TREMOR IN ANTI-MYELIN-ASSOCIATED GLYCOPROTEIN NEUROPATHY, Neurology, vol.73, issue.20, pp.1707-1708, 2009.
DOI : 10.1212/WNL.0b013e3181c1de66

P. Latino, C. Pellicano, F. Pontieri, and M. Giovannelli, Treatment with botulinum toxin for anti-MAG neuropathy-related arm tremor, Neurological Sciences, vol.18, issue.2, pp.10-1007, 2014.
DOI : 10.1007/s10072-014-1890-6

H. Hartung, H. Lehmann, B. Kieseier, and R. Hughes, Novel treatment for immune neuropathies on the horizon, Journal of the Peripheral Nervous System, vol.35, issue.2, pp.75-83, 2011.
DOI : 10.1111/j.1529-8027.2011.00334.x

A. Boivin, I. Pineau, and B. Barrette, Toll-Like Receptor Signaling Is Critical for Wallerian Degeneration and Functional Recovery after Peripheral Nerve Injury, Journal of Neuroscience, vol.27, issue.46, pp.12565-12576, 2007.
DOI : 10.1523/JNEUROSCI.3027-07.2007

J. Wang, Y. Jeelall, L. Ferguson, and K. Horikawa, Toll-Like Receptors and Cancer: MYD88 Mutation and Inflammation, Frontiers in Immunology, vol.123, issue.Pt 2, p.367, 2014.
DOI : 10.1182/blood-2013-12-543306

URL : http://doi.org/10.3389/fimmu.2014.00367

C. Jiménez, E. Sebastián, and M. Chillón, MYD88 L265P is a marker highly characteristic of, but not restricted to, Waldenström's macroglobulinemia. Leukemia, pp.1722-1728, 2013.

S. Treon, C. Tripsas, and K. Meid, Carfilzomib, rituximab, and dexamethasone (CaRD) treatment offers a neuropathy-sparing approach for treating Waldenström's macroglobulinemia. Blood, pp.503-510, 2014.